Emory and Eurofins launches EGL Genetics Diagnostics, adds 50 jobs
More than 100 personnel currently working at the Emory Genetics Lab on campus will retain their jobs at the new off-campus location. The venture will invest nearly $17 million to open a new lab spanning 61,000 square feet. The expanded lab will add more than 50 new jobs will be added in order to increase its capabilities.
“We are very excited that EGL has the opportunity to bring new jobs to DeKalb County and will continue its quest to be a leader in genetic testing,” said Dr. Madhuri Hegde, executive director of Emory Genetics Lab in a news release from the Georgia Department of Economic Development.
Emory Genetics Lab is renowned for testing rare genetic disorders. The laboratory has comprehensive testing facilities for cytogenetic, biochemical and molecular genetics. EGL is leading the industry in cancer testing and exome sequencing to aid diagnosis, prognosis, management and targeted drug therapy, in addition to expanded carrier testing capabilities.
Eurofins Scientific holds a 75 percent stake in the new venture. Eurofins was founded in 1987 to commercialize technology developed at the University of Nantes in Nantes, France. The company brought to market a patented analytical method used to verify the origin and purity of several types of food and beverages and to identify sophisticated fraud not detectable by other means.
Today Eurofins consists of a network of more than 200 laboratories in 38 countries. The company is a leader in food and pharmaceutical products testing and has expanded into the fields of environmental laboratory services, agriculture and genomic research.
“This joint venture with world-renowned medical and scientific teams at Emory University strengthens Eurofins’ growing footprint in the specialty clinical diagnostics market, and provides the group a truly unique platform to leverage its renowned competence in genomic testing to better serve the global healthcare community,” said Gilles Martin, Eurofins founder and CEO. “In combination with ViraCor, Boston Heart and Diatherix, EGL provides Eurofins a leading position in the most technologically-driven segment of the specialty clinical diagnostic testing market.”
Source: Eurofins Scientific
Source: Emory University